Association of genotypes of rs671 within ALDH2 with risk for gastric cardia adenocarcinoma in the Chinese Han population in high- and low-incidence areas =========================================================================================================================================================== * Lian-Qun Zhang * Xin Song * Xue-Ke Zhao * Jia Huang * Peng Zhang * Lu-Wen Wang * Hui Meng * Jian-Wei Ku * Guo-Qiang Kong * Tao Jiang * Xin-Min Li * Xiao-Long Lv * Teng Ma * Guo Yuan * Min-Jie Wu * Shou-Jia Hu * Shuang Lv * Tang-Juan Zhang * Ling-Fen Ji * Zong-Min Fan * Neng-Chao Wang * Yao-Wen Zhang * Fu-You Zhou * Li-Dong Wang ## Abstract **Objective:** This study aimed to determine if gastric cardia adenocarcinoma (GCA) risk was associated with the lys (A or *2) allele at the rs671 (glu504lys) polymorphism within the aldehyde dehydrogenase 2 ( *ALDH2*) gene in a Chinese Han population. We also aimed to investigate *ALDH2* genotypic distributions between subjects from high- and low-incidence areas for both GCA and esophageal squamous cell carcinoma (ESCC). **Methods:** We designed a case-control study including 2,686 patients with GCA and 3,675 control subjects from high- and low-incidence areas for both GCA and ESCC in China. TaqMan allele discrimination assay was used to genotype the rs671 polymorphism. *χ*2 test and binary logistic regression analysis were used to estimate the odds ratios for the development of GCA, and multivariate ordinal logistic regression was used to analyze *ALDH2* genotypic distributions among different groups. **Results:** Compared with *ALDH2*\*1/\*1 homozygotes, *ALDH2*\*1/\*2 and *ALDH2*\*2/\*2 carriers did not increase the risk for GCA in the Chinese Han population ( *P*>0.05). Interestingly, the ratio of homozygous or heterozygous *ALDH2* *2 carriers in high-incidence areas for both GCA and ESCC was lower than that in low-incidence areas ( *P*<0.001). **Conclusions:** Genotypes of rs671 at *ALDH2* may not increase GCA susceptibility in Chinese Han populations. In addition, the *ALDH2* genotypic distribution differs between Chinese Han populations from high- and low-incidence areas for both GCA and ESCC. Our findings may shed light on the possible genetic mechanism for the dramatic geographic differences of GCA occurrence in China. * Gastric cardia adenocarcinoma * rs671 * *ALDH2* ## Introduction More than half of gastric cardia cancer cases occur in China1. Gastric cardia adenocarcinoma (GCA) is one of the most common malignant diseases and often concurrently occurs with esophageal squamous cell carcinoma (ESCC) in China2. GCA bears many similarities to ESCC in terms of common geographic distribution and environmental risk factors, including low-intake of fruits and vegetables, nutritional deficiencies, and human papilloma virus infection2–6. These striking similarities suggest that a similar molecular mechanism may be involved in these two cancers. Indeed, a few susceptibility genes have been found in both ESCC and GCA, such as *PLCE1*, *C20orf54*7, *P53*8–10, *Cyclin D1*8, and *PCNA*10. *ALDH2* is the main enzyme responsible for acetaldehyde metabolism11,12. The human *ALDH2* gene is located at chromosome region 12q2413. A single-nucleotide polymorphism (SNP) in exon 12 of the *ALDH2* gene leads to amino acid change from glutamic acid to lysine at residue 504. The wild-type SNP (rs671) encodes glu (G) allele, which is referred to as the *ALDH2**1 allele. The variant (504lys) allele (A, formerly *ALDH2**2 and 487lys) reduces enzyme activity, which could result in malfunction of acetaldehyde metabolism14,15. Previous reports showed that rs671 polymorphism was associated with the risk for ESCC and stomach cancer in Japan16–18. However, the relationship between rs671 polymorphism and GCA risk is largely unknown. The incidence of GCA in the high-incidence areas for ESCC is 47.74-fold higher than that of the low-incidence areas in China19. Geographic distribution and environmental risk factors may be the reasons for the different incidences of GCA in high- and low-incidence areas for both GCA and ESCC. The genotype frequencies of *ALDH2* polymorphism vary among the different ethnic populations20. The *ALDH2**2 allele has not been observed in Caucasians, Africans, and Southeast Asians, but it is widely present in East Asians21,22. In East Asians, the *ALDH2* allele frequency was also found to be different among Japanese, Koreans, and Chinese23. In Chinese, the *ALDH2**2 allele frequency was lower in some aboriginal Chinese populations (e.g., Ami, Atayal, Bunun, Elunchan, Mongolian, and Paiwan) compared with Chinese Han population20. In the Chinese Han population, the *ALDH2**2 allele frequency is 0.17 to 0.29, the ratio of individuals with heterozygous *ALDH2**2 is 36% to 44%, and the ratio of individuals with homozygous *ALDH2**2 accounts for 7% to 8%24–26. However, no report was found concerning the genotype distribution of *ALDH2* in Chinese Han populations from the high- and low-incidence areas for both GCA and ESCC. The purpose of this study was to investigate the relationship between the risk for GCA and rs671 polymorphism within *ALDH2* gene in the Chinese Han population. In addition, we are interested in studying the rs671 genotypic distribution characteristics in Chinese Han populations from the high- and low-incidence areas for both GCA and ESCC. ## Materials and methods ### Study subjects A total of 2,686 GCA patients (2,081 males and 605 females with a mean age of 61±9 and 61±9 years, respectively) and 3,675 control subjects (1,866 males and 1,809 females with a mean age of 48±12 and 49±11 years, respectively) from high- and low-incidence areas for both GCA and ESCC in China between 2007 and 2010 were provided by Henan Key Laboratory for Esophageal Cancer Research. The *ALDH2* genotypic distributions fit the Hardy-Weinberg equilibrium test in this case-control study ( *P*=0.645; *P*=0.249). According to our genome-wide association study (GWAS) for ESCC, the enrollment criteria for cases and controls in this study were designed7. All cases and controls were Chinese Han residents from matched geographic areas without restriction on age, gender, ethnicity, and risk factor exposures. All cases were confirmed as GCA by pathology, and all controls were enrolled among subjects who underwent standard gastroscopy to eliminate the early GCA and did not have any family history of GCA (including first-, second-, and third-degree relatives). This study corresponded with the ethical standards and the Helsinki Declaration. ### Determination of the *ALDH2* genotype We analyzed the genotypic distributions of rs671 polymorphism in 2,686 cases and 3,675 normal controls, which were derived from replication of GWAS7. Flexi Gene DNA kit (QIAGEN, Germany) was used to extract the Genomic DNA from peripheral blood following the manufacturer’s protocol. TaqMan allele discrimination assay was employed for genotyping of the polymorphism (rs671) using the 7300 real-time polymerase chain reaction system (ABI7300; Applied Biosystems, Foster City, CA, USA). ### Statistical analysis Firstly, the allele frequency was measured by direct counting method and the deviation of *ALDH2* genotypic distributions from Hardy-Weinberg equilibrium was analyzed. Secondly, multivariate ordinal logistic regression analyzed *ALDH2* genotypic distributions between different groups, including gender, age, and area. Lastly, using the *χ*2-test and binary logistic regression analysis, the odds ratio for GCA was estimated by comparing the *ALDH2*\*2/\*2 and *ALDH2*\*1/\*2 genotypes with the homozygous wild-type genotype ( *ALDH2*\*1/\*1), stratified by gender, age, and area. All analyses were performed using SPSS software (version 19.0, SPSS Inc., Chicago, IL, USA). ## Results ### *ALDH2* genotypic distribution status based on the categories of different subgroups The differences in *ALDH2* genotypic distribution status in the categories of different subgroups were evaluated. Univariate analyses showed that the ratio of carriers homozygous or heterozygous for *ALDH2* *2 in the high-incidence areas for both GCA and ESCC was significantly lower than that in the low-incidence areas ( *ALDH2* 2*2 1.71% *vs*. 2.04%; *ALDH2* 1*2 22.83% *vs*. 27.02%, *P*<0.001). *ALDH2* genotypic distribution had no differences in gender, age, or group. Furthermore, this finding was consistent with the results of multivariate analysis (Table 1). View this table: [1](http://www.cancerbiomed.org/content/14/1/60/T1) 1 Distribution of the clinical variables according to the *ALDH2* genotype, *n* (%) ### The association between *ALDH2* genotypes and GCA risk Data from 3,675 controls and 2,686 GCA samples were used to evaluate the association between GCA risk and *ALDH2* genotypes. The ratio of *ALDH2* 2*2 and 1*2 genotypes in the GCA was slightly lower than that in control subjects (25.7% *vs*. 27.5%). However, univariate and multivariate analyses showed that the association between the *ALDH2* *2 allele and GCA risk in total was not significant ( *P*>0.05) (Table 2). View this table: [2](http://www.cancerbiomed.org/content/14/1/60/T2) 2 Distribution of cases and controls with regard to the *ALDH2* genotype, *n* (%) In different subgroups, univariate analyses exhibited a weak difference for *ALDH2* genotypic distribution between cases, and control had no difference in males (24.9% *vs*. 27.7%, *P*=0.049). Furthermore, multivariate analysis showed that the association between *ALDH2* *2 allele and GCA risk in all subgroups was not significant ( *P*>0.05) (Table 2). ## Discussion In this study, we demonstrate that rs671 variation is not associated with GCA risk. Further stratified analysis confirms that the ratio of ALDH2 2*2 and 1*2 genotypes in the GCA cases is not higher compared with that in control subjects among subgroups in terms of gender, age, or high- and low-incidence areas for both GCA and ESCC, while significant differences were found between the cases and controls in mean age and gender. These findings may be due to the nonexistent restrictions on age, gender, risk factor exposures or cancer stages in the case or control sample recruitments in our study and the peak age of 65 to 75, with men outnumbering women 2.5 to 1 for GCA patients in China19 Considering that the high-incidence record for GCA is 25.58/100,000 in China3, the researchers found that the maximum number of GCA patients estimated in the control group might be one case based on the current 3,675 control samples. Therefore, the controls should not confound the association of the risk for GCA with the *ALDH2* genotypes. Our GWAS confirmed that rs671 polymorphism within *ALDH2* gene is not associated with the susceptibility of ESCC in the Chinese Han population7. The coincident results suggested that rs671 polymorphism may share a similar contribution in both esophageal and gastric cardia carcinogenesis in the Chinese Han population. The heterozygous or homozygous allele 504lys carrier has a reduced ability to remove acetaldehyde, which in turn leads to reduced ability for drinking20,27. According to Mendelian randomization, environmental exposure was determined by genetic variants, which should be associated with the disease risk28. Therefore, *ALDH2* \*1/\*2 or *ALDH2* \*2/\*2 genotypes carrier has much lower capability to metabolize acetaldehyde, which greatly reduced the risk for alcohol exposure20. Drinking behavior could be regulated by *ALDH2* genotypes in the Japanese and Chinese populations27,29. In this study, the number of individuals in the GCA homozygous or heterozygous for *ALDH2* *2 was slightly lower than that in control subjects. This suggests that the consumption frequency of alcohol may be higher in the case group than in the control group, and the consumption of alcohol is associated with increased risk of GCA. This conjecture is consistent with the previous results30,31. In addition, we initially found that distribution of *ALDH2* genotypes is different in Chinese Han cohorts between high- and low-incidence areas. The genetic background of residents from high- and low-incidence areas for both GCA and ESCC may be different. Previous reports including our GWAS studies show that alcohol drinking interacted with *ALDH2* (rs671) on ESCC susceptibility7,32,33. Owing to the similar underlying molecular mechanism involved in both GCA and ESCC, the researchers found that the rs671 variation might interact with alcohol consumptions on GCA susceptibility. Alcohol intakes vary widely in different regions of China. Thus, the different genotype distribution of *ALDH2* and drinking consumptions of the residents may be one of the reasons why mortality rate of GCA varies greatly in high- and low-incidence areas for both GCA and ESCC. Limitations of this study: we were unable to further explore the interaction effects of *ALDH2* genotypes and alcohol consumption on the risk for GCA because this data does not contain alcohol history. In conclusion, genotypes of rs671 at *ALDH2* are not involved in GCA susceptibility in the Chinese Han population. Interestingly, the frequency of homozygous or heterozygous *ALDH2* *2 carriers in the Chinese Han population in the high-incidence areas for both GCA and ESCC was lower than in the low-incidence areas, suggesting the possible genetic mechanism for the dramatic geographic difference of GCA occurrence in China. ## Acknowledgements This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81472323), Top Talent Support Project of Zhengzhou University (Grant No. ZDGD 13001) and Innovation Scientists and Technicians Troop Construction Projects of Henan Province (Grant No. 3047). ## Footnotes * **Conflict of interest statement** No potential conflicts of interest are disclosed. * Received November 5, 2016. * Accepted December 23, 2016. * Copyright: © 2017, Cancer Biology & Medicine [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) This is an open access article distributed under the terms of the [Creative Commons Attribution License (CC BY) 4.0](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. ## References 1. 1. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015; 64: 1881–8. [Abstract/FREE Full Text](http://www.cancerbiomed.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiZ3V0am5sIjtzOjU6InJlc2lkIjtzOjEwOiI2NC8xMi8xODgxIjtzOjQ6ImF0b20iO3M6MTc6Ii9jYm0vMTQvMS82MC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 2. 2. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the linxian general population trial cohort in china. Int J Cancer. 2005; 113: 456–63. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/ijc.20616&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=15455378&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000225900600017&link_type=ISI) 3. 3. He YT, Hou J, Chen ZF, Qiao CY, Song GH, Meng FS, et al. Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China. Eur J Cancer Prev. 2008; 17: 71–6. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1097/CEJ.0b013e3282b6fd97&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=18287862&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000253920000001&link_type=ISI) 4. 4. Su M, Liu M, Tian DP, Li XY, Zhang GH, Yang HL, et al. Temporal 18. trends of esophageal cancer during 1995-2004 in nanao island, an extremely high-risk area in china. Eur J Epidemiol. 2007; 22: 43–8. 5. 5. Ding GC, Ren JL, Chang FB, Li JL, Yuan L, Song X, et al. Human papillomavirus DNA and P16INK4A expression in concurrent esophageal and gastric cardia cancers. World J Gastroenterol. 2010; 16: 5901–6. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.3748/wjg.v16.i46.5901&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=21155014&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 6. 6. Bahmanyar S, Ye WM. Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: A population-based case-control study in sweden. Nutr Cancer. 2006; 54: 171–8. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1207/s15327914nc5402_3&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=16898861&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000241742600003&link_type=ISI) 7. 7. Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies a susceptibility locus at PLCE1. Nat Genet. 2010; 42: 759–63. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1038/ng.648&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=20729853&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000281388400010&link_type=ISI) 8. 8. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong JY, Shao P, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994; 59: 514–9. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=7960222&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 9. 9. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features. BMC Cancer. 2002; 2: 8. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1186/1471-2407-2-8&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=11978184&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 10. 10. Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, et al. Alterations of p53 and pcna in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol. 2003; 9: 16–21. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.3748/wjg.v9.i1.16&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=12508343&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 11. 11. Bosron WF, Li TK. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology. 1986; 6: 502–10. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/hep.1840060330&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=3519419&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=A1986C694600029&link_type=ISI) 12. 12. Chen CH, Ferreira JCB, Gross ER, Mochly-Rosen D. Targeting aldehyde dehydrogenase 2: New therapeutic opportunities. Physiol Rev. 2014; 94: 1–34. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1152/physrev.00017.2013&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=24382882&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 13. 13. Raghunathan L, Hsu LC, Klisak I, Sparkes RS, Yoshida A, Mohandas T. Regional localization of the human genes for aldehyde dehydrogenase-1 and aldehyde dehydrogenase-2. Genomics. 1988; 2: 267–9. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/0888-7543(88)90012-2&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=3397064&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 14. 14. Yoshida A, Hsu LC, Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol. 1991; 40: 255–87. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1016/S0079-6603(08)60844-2&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=2031085&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=A1991GM71500007&link_type=ISI) 15. 15. Yoshida A, Huang IY, Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in orientals. Proc Natl Acad Sci U S A. 1984; 81: 258–61. [Abstract/FREE Full Text](http://www.cancerbiomed.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czo4OiI4MS8xLzI1OCI7czo0OiJhdG9tIjtzOjE3OiIvY2JtLzE0LzEvNjAuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 16. 16. Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, Kajiyama Y, et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with adh1b and/or aldh2 risk alleles. Gut. 2010; 59: 1457–64. [Abstract/FREE Full Text](http://www.cancerbiomed.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoiZ3V0am5sIjtzOjU6InJlc2lkIjtzOjEwOiI1OS8xMS8xNDU3IjtzOjQ6ImF0b20iO3M6MTc6Ii9jYm0vMTQvMS82MC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 17. 17. Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, Kawaguchi T, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009; 137: 1768–75. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1053/j.gastro.2009.07.070&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=19698717&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000271500700034&link_type=ISI) 18. 18. Matsuo K, Oze I, Hosono S, Ito H, Watanabe M, Ishioka K, et al. The aldehyde dehydrogenase 2(ALDH2) glu504lys polymorphism interacts with alcohol drinking in the risk of stomach cancer. Carcinogenesis. 2013; 34: 1510–5. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1093/carcin/bgt080&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=23455379&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000321753000011&link_type=ISI) 19. 19. Wei KR, Chen ZF, Peng XB, Li DF, Song GH, Liang ZH, et al. Comparison of gastric cardiac cancer incidence between areas with low and high esophageal cancer incidence. Modern Oncol. 2014; 22: 59–63. 20. 20. Li DW, Zhao HY, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet. 2012; 131: 725–37. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1007/s00439-011-1116-4&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=22102315&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 21. 21. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet. 1992; 88: 344–6. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=1733836&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=A1992HB03300018&link_type=ISI) 22. 22. Brennan P, Lewis S, Hashibe M, Bell DA, Boffetta P, Bouchardy C, et al. Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: A huge review. Am J Epidemiol. 2004; 159: 1–16. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1093/aje/kwh003&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=14693654&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000187974800001&link_type=ISI) 23. 23. Hamajima N, Takezaki T, Tajima K. Allele frequencies of 25 polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev. 2002; 3: 197–206. [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=12718576&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 24. 24. Xia JQ, Song J, Zhang Y, An NN, Ding L, Zhang Z. Effect of aldehyde dehydrogenase 2 gene polymorphism on hemodynamics after nitroglycerin intervention in northern chinese han population. Chin Med J (Engl). 2015; 128: 180–5. 25. 25. Guo YM, Wang Q, Liu YZ, Chen HM, Qi Z, Guo QH. Genetic polymorphisms in cytochrome P4502E1, alcohol and aldehyde dehydrogenases and the risk of esophageal squamous cell carcinoma in Gansu Chinese males. World J Gastroenterol. 2008; 14: 1444–9. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.3748/wjg.14.1444&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=18322963&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) 26. 26. Lee CH, Lee JM, Wu DC, Goan YG, Chou SH, Wu IC, et al. Carcinogenetic impact of ADH1B and ALDH2 genes on squamous cell carcinoma risk of the esophagus with regard to the consumption of alcohol, tobacco and betel quid. Int J Cancer. 2008; 122: 1347–56. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/ijc.23264&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=18033686&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000253302800020&link_type=ISI) 27. 27. Takeuchi F, Isono M, Nabika T, Katsuya T, Sugiyama T, Yamaguchi S, et al. Confirmation of ALDH2 as a major locus of drinking behavior and of its variants regulating multiple metabolic phenotypes in a Japanese population. Circul J. 2011; 75: 911–8. 28. 28. Smith GD, Ebrahim S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32: 1–22. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1093/ije/dyg070&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=12689998&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000182341300001&link_type=ISI) 29. 29. Quillen EE, Chen XD, Almasy L, Yang F, He H, Li X, et al. ALDH2 is associated to alcohol dependence and is the major genetic determinant of "daily maximum drinks” in a gwas study of an isolated rural Chinese sample. Am J Med Genet B Neuropsychiatr Genet. 2014; 165B: 103–10. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/ajmg.b.32213&link_type=DOI) 30. 30. Lagergren J, Bergstrom R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer. 2000; 85: 340–6. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/(SICI)1097-0215(20000201)85:3<340::AID-IJC8>3.0.CO;2-N&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=10652424&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=000084588400008&link_type=ISI) 31. 31. Kabat GC, Ng SKC, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control. 1993; 4: 123–32. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1007/BF00053153&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=8481491&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom) [Web of Science](http://www.cancerbiomed.org/lookup/external-ref?access_num=A1993KR65100007&link_type=ISI) 32. 32. Zhao TT, Wang C, Shen LL, Gu DY, Xu Z, Zhang XL, et al. Clinical significance of ALDH2 rs671 polymorphism in esophageal cancer: Evidence from 31 case-control studies. Onco Targets Ther. 2015; 8: 649–59. 33. 33. Wu M, Chang SC, Kampman E, Yang J, Wang XS, Gu XP, et al. Single nucleotide polymorphisms of ADH1B, ADH1C and ALDH2 genes and esophageal cancer: A population-based case-control study in China. Int J Cancer. 2013; 132: 1868–77. [CrossRef](http://www.cancerbiomed.org/lookup/external-ref?access_num=10.1002/ijc.27803&link_type=DOI) [PubMed](http://www.cancerbiomed.org/lookup/external-ref?access_num=22930414&link_type=MED&atom=%2Fcbm%2F14%2F1%2F60.atom)